Guangdong Pharmaceutical Association Expands Off-Label Drug Use Catalogue for 2024
The Guangdong Pharmaceutical Association (GDPA) has released the Off-label Drug Use Catalogue for the year...
Envonalkib, Chia Tai Tianqing’s Next-Gen ALK Inhibitor, Wins NMPA Approval for Untreated ALK+ NSCLC
Chia Tai Tianqing’s next-generation ALK inhibitor, envonalkib, has received approval from the National Medical Products...
Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of...
AstraZeneca Restructures County Oncology Team to Enhance Vertical Alignment
AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin...
Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC
Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...
MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...
Kintor Pharmaceutical Initiates Phase II Clinical Trial for Acne Treatment GT20029 in China
Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the enrollment...
RemeGen’s Telitacicept Receives NMPA Approval for Clinical Trial in IgG4 Related Diseases
RemeGen (HKG: 9995), a Chinese pharmaceutical company, has announced that it has received clinical trial...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Breast Cancer Drug Combo
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that it...
Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions
Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling...
Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services
The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...
Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits
Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...
BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US
BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...
Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US
Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...
MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...